Correlation Between Morgan Stanley and Mineralys Therapeutics

Can any of the company-specific risk be diversified away by investing in both Morgan Stanley and Mineralys Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Morgan Stanley and Mineralys Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Morgan Stanley and Mineralys Therapeutics Common, you can compare the effects of market volatilities on Morgan Stanley and Mineralys Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Morgan Stanley with a short position of Mineralys Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Morgan Stanley and Mineralys Therapeutics.

Diversification Opportunities for Morgan Stanley and Mineralys Therapeutics

-0.41

Correlation Coefficient

Morgan Stanley  Mineralys Therapeutics

Very good diversification

The 3 months correlation between Morgan and Mineralys is -0.41. Overlapping area represents the amount of risk that can be diversified away by holding Morgan Stanley and Mineralys Therapeutics Common in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Mineralys Therapeutics and Morgan Stanley is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Morgan Stanley are associated (or correlated) with Mineralys Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Mineralys Therapeutics has no effect on the direction of Morgan Stanley i.e., Morgan Stanley and Mineralys Therapeutics go up and down completely randomly.

Pair Corralation between Morgan Stanley and Mineralys Therapeutics

Allowing for the 90-day total investment horizon Morgan Stanley is expected to generate 0.24 times more return on investment than Mineralys Therapeutics. However, Morgan Stanley is 4.23 times less risky than Mineralys Therapeutics. It trades about 0.5 of its potential returns per unit of risk. Mineralys Therapeutics Common is currently generating about 0.12 per unit of risk. If you would invest  8,926  in Morgan Stanley on February 17, 2024 and sell it today you would earn a total of  1,026  from holding Morgan Stanley or generate 11.49% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Very Weak
Accuracy	100.0%
Values	Daily Returns

Morgan Stanley  vs.  Mineralys Therapeutics Common

Morgan Stanley

Risk-Adjusted Performance

14 of 100

Good

Compared to the overall equity markets, risk-adjusted returns on investments in Morgan Stanley are ranked lower than 14 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively weak basic indicators, Morgan Stanley unveiled solid returns over the last few months and may actually be approaching a breakup point.

Mineralys Therapeutics

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Mineralys Therapeutics Common has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest fragile performance, the Stock's basic indicators remain stable and the newest uproar on Wall Street may also be a sign of mid-term gains for the firm private investors.

Pair Trading with Morgan Stanley and Mineralys Therapeutics

The main advantage of trading using opposite Morgan Stanley and Mineralys Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Morgan Stanley position performs unexpectedly, Mineralys Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Mineralys Therapeutics will offset losses from the drop in Mineralys Therapeutics' long position.

The idea behind Morgan Stanley and Mineralys Therapeutics Common pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.